LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; no. suppl_8
Main Authors Kim, E S, Velcheti, V, Mekhail, T, Leal, T A, Dowell, J E, Tsai, M L, Dakhil, C S R, Stella, P, Shen, V, Hu, S, Paul, S M, Shames, D S, Schleifman, E, Fabrizio, D A, Yun, C, Phan, S, Socinski, M A
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.10.2018
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy424.067